Literature DB >> 16280352

Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).

J C Hobart1, A Riazi, A J Thompson, I M Styles, W Ingram, P J Vickery, M Warner, P J Fox, J P Zajicek.   

Abstract

Spasticity is most commonly defined as an inappropriate, velocity dependent, increase in muscle tonic stretch reflexes, due to the amplified reactivity of motor segments to sensory input. It forms one component of the upper motor neuron syndrome and often leads to muscle stiffness and disability. Spasticity can, therefore, be measured through electrophysiological, biomechanical and clinical evaluation, the last most commonly using the Ashworth scale. None of these techniques incorporate the patient experience of spasticity, nor how it affects people's daily lives. Consequently, we set out to construct a rating scale to quantify the perspectives of the impact of spasticity on people with multiple sclerosis. Qualitative methods (in-depth patient interviews and focus groups, expert opinion and literature review) were used to develop a conceptual framework of spasticity impact, and to generate a pool of items with the potential to convert this framework into a rating scale with multiple dimensions. This item pool was administered, in the form of a questionnaire, to a sample of people with multiple sclerosis and spasticity. Guided by Rasch analysis, we constructed and validated a rating scale for each component of the conceptual framework. Decisions regarding item selection were based on the integration and assimilation of seven specific analyses including clinical meaning, ordering of thresholds, fit statistics and differential item functioning. The qualitative phase (17 patient interviews, 3 focus groups) generated 144 potential scale items and a conceptual model with eight components addressing symptoms (muscle stiffness, pain and discomfort and muscle spasms,), physical impact (activities of daily living, walking and body movements) and psychosocial impact (emotional health, social functioning). The first postal survey was sent to 272 people with multiple sclerosis and had a response rate of 88%. Findings supported the development of scales for each component but demonstrated that five item response options were too many. The 144-item questionnaire, reformatted with four-item response options, was administered with four validating instruments to an independent sample of 259 people with multiple sclerosis (response rate 78%). From the responses, an 88-item instrument with eight subscales was developed that satisfied criteria for reliable and valid measurement. Correlations with other measures were consistent with predictions. The 88-item Multiple Sclerosis Spasticity Scale (MSSS-88) is a reliable and valid, patient-based, interval-level measure of the impact of spasticity in multiple sclerosis. It has the potential to advance outcomes measurement in clinical trials and clinical practice, and provides a new perspective in the clinical evaluation of spasticity.

Entities:  

Mesh:

Year:  2005        PMID: 16280352     DOI: 10.1093/brain/awh675

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

1.  Novel application of a Wii remote to measure spasticity with the pendulum test: Proof of concept.

Authors:  Chien-Hung Yeh; Chi-Yao Hung; Yung-Hung Wang; Wei-Tai Hsu; Yi-Chung Chang; Jia-Rong Yeh; Po-Lei Lee; Kun Hu; Jiunn-Horng Kang; Men-Tzung Lo
Journal:  Gait Posture       Date:  2015-11-06       Impact factor: 2.840

2.  Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis.

Authors:  Francesco Mori; Concetta Ljoka; Elisabetta Magni; Claudia Codecà; Hajime Kusayanagi; Fabrizia Monteleone; Andrea Sancesario; Giorgio Bernardi; Giacomo Koch; Calogero Foti; Diego Centonze
Journal:  J Neurol       Date:  2011-02-01       Impact factor: 4.849

3.  Measuring outcomes in clinical trials of stroke: time for state-of-the-art clinical trials to reject state-of-the-ark rating scales.

Authors:  Jeremy Hobart
Journal:  J Neurol       Date:  2007-08       Impact factor: 4.849

Review 4.  Spasticity Measurement.

Authors:  Belgin Petek Balci
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

5.  The 88-item Multiple Sclerosis Spasticity Scale: a Rasch validation of the Italian version and suggestions for refinement of the original scale.

Authors:  Leonardo Pellicciari; Marcella Ottonello; Andrea Giordano; Caterina Albensi; Franco Franchignoni
Journal:  Qual Life Res       Date:  2018-09-20       Impact factor: 4.147

Review 6.  Assessment and Measurement of Spasticity in MS: State of the Evidence.

Authors:  Cinda L Hugos; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-30       Impact factor: 5.081

7.  Plantarflexor weakness negatively impacts walking in persons with multiple sclerosis more than plantarflexor spasticity.

Authors:  Joanne M Wagner; Theodore R Kremer; Linda R Van Dillen; Robert T Naismith
Journal:  Arch Phys Med Rehabil       Date:  2014-02-28       Impact factor: 3.966

8.  Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

Authors:  Uwe K Zettl; Thomas Henze; Ute Essner; Peter Flachenecker
Journal:  Eur J Health Econ       Date:  2013-12-01

9.  Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.

Authors:  Lanting Lu; Hilary Pearce; Chris Roome; James Shearer; Iain A Lang; Ken Stein
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

10.  Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort.

Authors:  John P Zajicek; Wendy M Ingram; Jane Vickery; Siobhan Creanor; Dave E Wright; Jeremy C Hobart
Journal:  BMC Neurol       Date:  2010-10-07       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.